Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. The company offers anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products… Read more
Jiangsu Aidea Pharmaceutical Co Ltd (688488) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.003x
Based on the latest financial reports, Jiangsu Aidea Pharmaceutical Co Ltd (688488) has a cash flow conversion efficiency ratio of 0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥3.56 Million) by net assets (CN¥1.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jiangsu Aidea Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Jiangsu Aidea Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jiangsu Aidea Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Aidea Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ral Yatirim Holding AS
IS:RALYH
|
0.214x |
|
Peoples Fin
NASDAQ:PFIS
|
0.029x |
|
Scientex Bhd
KLSE:4731
|
0.002x |
|
Dakota Gold Corp.
NYSE MKT:DC
|
-0.085x |
|
Citycon Oyj
PINK:COYJF
|
0.020x |
|
GULF KEYSTONE PETR.
F:GVP1
|
N/A |
|
Guangzhou Hangxin Aviation Technology Co Ltd
SHE:300424
|
0.067x |
|
HEARTLAND GRP HLDGS
F:73X
|
N/A |
Annual Cash Flow Conversion Efficiency for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.07 Billion | CN¥-37.50 Million | -0.035x | +76.21% |
| 2023-12-31 | CN¥1.13 Billion | CN¥-166.22 Million | -0.148x | -91.31% |
| 2022-12-31 | CN¥1.20 Billion | CN¥-92.55 Million | -0.077x | -717.31% |
| 2021-12-31 | CN¥1.31 Billion | CN¥-12.37 Million | -0.009x | -122.87% |
| 2020-12-31 | CN¥1.36 Billion | CN¥56.17 Million | 0.041x | -59.12% |
| 2019-12-31 | CN¥556.24 Million | CN¥56.20 Million | 0.101x | +257.64% |
| 2018-12-31 | CN¥522.71 Million | CN¥-33.50 Million | -0.064x | +50.96% |
| 2017-12-31 | CN¥514.09 Million | CN¥-67.18 Million | -0.131x | -225.46% |
| 2016-12-31 | CN¥300.40 Million | CN¥31.29 Million | 0.104x | -- |